ArticleMarine drugs2012
In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice.
Article in Marine drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 89 citations in OpenAlex.
- Algae-Derived Bioactive Compounds as Platforms for Translational Biotechnology and Health Applications.Biotech (Basel (Switzerland)) · 2026Review
- Carotenoids for Antiaging: Nutraceutical, Pharmaceutical, and Cosmeceutical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Natural STAT3 Inhibitors for Cancer Treatment: A Comprehensive Literature Review.Recent patents on anti-cancer drug discovery · 2024Review
- Valuable pigments from microalgae: phycobiliproteins, primary carotenoids, and fucoxanthin.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Review
- Fucoxanthin suppresses the malignant progression of ovarian cancer by inactivating STAT3/c-Myc signaling.American journal of translational research · 2023Article
- Brown Algae as Functional Food Source of Fucoxanthin: A Review.Foods (Basel, Switzerland) · 2022Review
- Fucoxanthin: A Promising Phytochemical on Diverse Pharmacological Targets.Frontiers in pharmacology · 2022Review
- Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.Molecules (Basel, Switzerland) · 2021Review
- Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Anti-Inflammatory and Anticancer Effects of Microalgal Carotenoids.Marine drugs · 2021Review
- Fucoxanthin induced apoptotic cell death in oral squamous carcinoma (KB) cells.Bioinformation · 2021Article
- Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy.International journal of molecular sciences · 2020Review
- The Yemeni Brown AlgaeBioMed research international · 2020Article
- Chemopreventive Effect of β-Cryptoxanthin on Human Cervical Carcinoma (HeLa) Cells Is Modulated through Oxidative Stress-Induced Apoptosis.Antioxidants (Basel, Switzerland) · 2019Article
- Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.Drug delivery · 2019Article
- Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer.Journal of cellular and molecular medicine · 2019Article
- The anticancer effects and mechanisms of fucoxanthin combined with other drugs.Journal of cancer research and clinical oncology · 2019Review
- Article
- Seaweed Secondary Metabolites In Vitro and In Vivo Anticancer Activity.Marine drugs · 2018Review
- Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous in vitro researches have showed that fucoxanthin, a natural carotenoid isolated from sargassum, can inhibit proliferation or induce apoptosis in human neuroblastoma, hepatoma, leukemia, colon carcinoma, prostate cancer or urinary bladder cancer cells. But the precise mechanism by which fucoxanthin exerts anticarcinogenic effects is not yet fully understood. In this study, we performed an in vivo study to investigate the anti-tumor effect and mechanisms of fucoxanthin on xenografted sarcoma 180 (S180) in mice. Results revealed that fucoxanthin significantly inhibited the growth of sarcoma at the dose of 50 or 100 mg/kg. TUNEL analysis showed that the number of positive cells in the fucoxanthin-treated group was higher than that in the control group. Western blotting analysis also revealed the suppressed expression of bcl-2 and enhanced expression of cleaved caspase-3 by fucoxanthin. In addition, immunohistochemistry analysis and Western blotting analysis showed that fucoxanthin significantly decreased the expressions of survivin and vascular endothelial growth factor (VEGF). Most importantly, fucoxanthin inhibited the expressions of the epidermal growth factor receptor (EGFR) and STAT3 and phosphorylated STAT3 proteins. These results indicated that in vivo induction of apoptosis by fucoxanthin is associated with down-regulating STAT3/EGFR signaling in S180 xenografts-bearing mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.